According to Rigel Pharmaceuticals's latest financial reports the company has a price-to-book ratio of 1.71777.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Year | P/B ratio | Change |
---|---|---|
2024-12-31 | 88.4 | -1101.45% |
2023-12-31 | -8.83 | -53.64% |
2022-12-31 | -19.0 | -227.62% |
2021-12-31 | 14.9 | -14.17% |
2020-12-31 | 17.4 | 160.2% |
2019-12-31 | 6.68 | 90.9% |
2018-12-31 | 3.50 | -38.04% |
2017-12-31 | 5.65 | 31.97% |
2016-12-31 | 4.28 | 42.52% |
2015-12-31 | 3.00 | 92.68% |
2014-12-31 | 1.56 | 30.1% |
2013-12-31 | 1.20 | -38.86% |
2012-12-31 | 1.96 | -17.69% |
2011-12-31 | 2.38 | 0.47% |
2010-12-31 | 2.37 | -47.32% |
2009-12-31 | 4.50 | 60.06% |
2008-12-31 | 2.81 | -71.02% |
2007-12-31 | 9.70 | 182.95% |
2006-12-31 | 3.43 | 79.36% |
2005-12-31 | 1.91 | -79.19% |
2004-12-31 | 9.18 | 28.89% |
2003-12-31 | 7.12 | 260.12% |
2002-12-31 | 1.98 |